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Background: Intravenous (IV) artesunate is the treatment of choice for severe malaria. In Europe, this treatment is
only available in a few countries via named patient programmes (NPPs). As a case study, the legal and organisational
aspects and pharmacovigilance of these NPPs and possibilities for harmonisation within the EU were studied over time
and space using IV artesunate (Malacef) in the Netherlands, Belgium and France.
Methods: The legal base and organisation of NPPs in the Netherlands, Belgium and France were studied. The diffusion
and cumulative availability of IV artesunate and the pharmacovigilance components were compared among the three
countries using distribution data from the period 2007 through 2012.
Results: Artesunate has quickly gained acceptance for treating severe malaria in the Netherlands, whereas both Belgium
and France have introduced this treatment more hesitantly. This difference in acceptance is due to differences in the
implementation of NPP legislation among the countries. France currently has a proactive system in which treatment
requires the permission for each patient and an intensive follow-up protocol. On the other hand, Belgium and Dutch
NPPs are more dependent on the investigators’ initiative and are therefore potentially faster and more flexible, facilitating
the discovery of adverse effects that have not been reported by more formal comparative clinical trials.
Conclusions: NPPs provide a unique opportunity to study both the benefits and risks of unregistered products for
treating rare diseases, provided that the patients are actively vigilated. Thus, we recommend that NPPs should be
harmonised throughout Europe in order to ensure equal availability of treatment and therapeutic benefit to all
Europeans without compromising patient safety.
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Severe malaria is a medical emergency that has a mortal-
ity rate of nearly 100% if not treated promptly [1].
Artesunate is the current drug of choice for treating
severe malaria [1]. The anti-malarial properties of artesu-
nate are superior to quinine, and artesunate significantly
reduced mortality among both children and adults in the
two largest trials conducted to date for treating severe fal-
ciparum malaria [2,3].* Correspondence: a.r.vegter@amc.uva.nl
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distribution, and reproduction in any mediumDespite its clear advantages over other treatments, IV
artesunate is not currently available in either Europe or
the United States, and this is due to two separate issues.
Firstly, whether evidence obtained from malaria-endemic
regions can be generalised to the European population is a
subject of debate. Moreover, whether it is justified, feasible
and necessary to conduct comparative studies for European
patients given the currently available evidence and the rec-
ommendation by the World Health Organization (WHO)
to use artesunate as the drug of choice for treating severe
malaria [1,4] is also under discussion. Secondly, artesunate
is not manufactured in accordance with European Good
Manufacturing Practice (EU-GMP), which is a require-
ment for market authorisation. The WHO recently prequa-
lified the Chinese version of this product [5] after theed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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China) improved their production process, thus ensuring
that the drug is manufactured in compliance with WHO-
GMP requirements. Nevertheless, this standard is not con-
sidered to reach the same GMP level as the EU-GMP. In
both the EU and the United States, IV artesunate does not
have market authorisation yet.
Although marketing and supplying unauthorised phar-
maceutical products are prohibited in the EU, access to
drugs prior to their formal approval may be granted for
individual patient care, provided no currently registered
alternative is available within the EU. The European legal
framework provides two situations in which non-licenced
medical products can be given to patients; these situations
are compassionate-use programmes (CUPs) and named
patient programmes (NPPs) [6].
CUPs apply to a group of patients with a medical con-
dition for which a drug therapy is being studied and
who do not (or no longer) participate in the study and
who wish to be treated with the investigational drug.
NPPs, as the name suggests, refer to the use of a drug in
an individual patient and are the responsibility of the
prescribing physician. Although a regulatory framework
exists for access to unauthorised medicinal products at
the European level, the approval, implementation and
oversight of such programmes remain the responsibility
of the individual country.
Prior to 2007, IV artesunate was not available in
Europe, despite an increasing demand from physicians
who were treating malaria. In response to this demand,
clinicians at the Academic Medical Centre, Amsterdam,
the Netherlands (including Dr. P.J. de Vries) initiated an
NPP in collaboration with ACE Pharmaceuticals BV (in
Zeewolde, the Netherlands), a company that specialises in
orphan drugs and medical-need products, after permis-
sion was granted by the Dutch Health Care Inspectorate.
IV artesunate is imported from Guilin (Shanghai, China)
by ACE Pharmaceuticals; following an extensive series
of quality and sterility controls, the drug is then released
for distribution under the trade name Malacef® 60. The
product is kept as an emergency stock in the hospital
pharmacies and is prescribed for individual patients and
accompanied by a medical statement from the prescribing
physician. In parallel with this NPP, in February 2007 an
orphan designation (EU/3/07/430) was granted by the
European Commission to ACE Pharmaceuticals for using
IV artesunate to treat malaria.
The objective of this study was to describe and com-
pare the availability of IV artesunate over time and space
under named patient programmes in the Netherlands and
two additional European countries (Belgium and France)
from 2007 through 2012, with the overall aim of identify-
ing patterns that will be useful for harmonising NPPs
throughout the EU.Methods
Legal basis and description of implementation of NPPs in
the Netherlands, Belgium and France
In Europe, the legal framework for NPPs i.e. the supply
of unlicensed medicines for use by individual patients is
governed by EU member countries as described in Art-
icle 5 of Directive 2001/83/EC. The implementation and
regulatory requirements of such programmes vary widely
among EU countries. The national legislation that gov-
erns NPPs and their implementation in the Netherlands,
Belgium and France, the three countries in which Malacef
is available through an NPP, was studied by searching for
Internet-based documents on national government web-
sites and websites of national authorities or the agencies
responsible for decision-making with respect to medicines
and healthcare products. The search was performed in
January 2013.
Availability of Malacef in the Netherlands, Belgium
and France
The process of making Malacef available to prescribers
and the pharmacovigilance of Malacef were studied by
requesting data from the supplier and from pharmaceut-
ical and medical professionals. ACE Pharmaceuticals pro-
vided pharmaceutical distribution data regarding Malacef
in the Netherlands, Belgium and France. The presence of
artesunate treatment for at least one adult patient with se-
vere malaria was used as a measure of availability. Cumu-
lative availability was calculated using distribution data
and was grouped according to the following three hospital
types: university medical centres (UMCs), teaching hospi-
tals (i.e. general hospitals affiliated with a university medical
centre) and general hospitals. In France, because no distinc-
tion exists between the first two hospital types, French
UMCs and teaching hospitals were grouped under the
heading Centre Hospitalier Universitaire (CHU). To allow
a direct comparison between countries, the availability of
Malacef in the Netherlands, Belgium and France was ex-
pressed per population capita by dividing the number of
Malacef vials ordered by each country by that country’s
total population; for plotting the data, the resulting value
was then multiplied by 1000.
Pharmacovigilance
Pharmacovigilance data were proactively collected as
previously described [7] for all Dutch patients who were
treated with IV artesunate in the period from November
2007 through December 2010 and for all Belgian pa-
tients who were treated in the period from January 2009
through December 2010. For French patients, safety data
were received from the Agence National de Securité
du Medicament et des Produits de Santé (ANSM), the
national French authority in charge of, among others,
pharmacovigilance.
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Legal basis and implementation of NPPs in the
Netherlands, Belgium and France
For the Netherlands, the legal basis of NPPs is laid down
in Article 3.17 of the Regulation of the Dutch Medicines
Act [8]. The competent Dutch authority that is respon-
sible for decision-making regarding medicines and
healthcare products is the CBG-MEB (Medicines Evalu-
ation Board) [9]. Because dispensing a medicinal product
on the basis of a physician’s statement (stating a named
patient, the indication and the product name) falls under
the jurisdiction of the Health Care Inspectorate, we also
accessed their website [10].
In Belgium, an NPP can be implemented in accord-
ance with the law regarding medicinal products of
25/03/1964 [11], revised on 1 May, 2006 (art.6 quarter
§1, 1°), and its Royal Decree dated 14/12/2006 (art. 102
and 105). The Federal Agency for Medicines and Health
Products (FAMHP) [12] is the competent Belgian author-
ity responsible for the quality, safety and efficacy of medi-
cines and healthcare products.
In France, using medicinal products that lack market-
ing authorisation is conditioned upon first obtaining a
Temporary Authorisation for Use (ATU) from the ANSM,
formerly known as AFSSAPS [13]. The general principles
guiding the ATU and its legal provision were already laid
down in 1994.
The additional requirements for the implementation
and pharmacovigilance of an NPP in all three countries
are summarised in Table 1.
Implementation of IV artesunate NPP in the Netherlands,
Belgium and France
IV artesunate in the Netherlands has been introduced by a
letter written by a healthcare professional internal medi-
cines (P.J. de Vries, AMC) and an industrial pharmacist
(C.K.W van Veldhuizen, ACE Pharmaceuticals) to medical
professionals in the field of tropical medicines. The letter
explained the status of the product and the procedures re-
garding how to order the product. In addition, the letter
recommended that each hospital maintain an emergency
stock of IV artesunate that is sufficient to treat at least one
patient. In Belgium, prescribers at the Institute of Tropical
Medicine in Antwerp initiated an NPP to gain access to
Malacef by approaching ACE Pharmaceuticals, who in
turn consulted the Federal Agency for Medicines and
Health Products (FAMHP) for instalment of the pro-
gramme in Belgium.
In France, temporary authorisation was initiated by
ACE Pharmaceuticals in collaboration with the National
Reference Centre for Malaria (CNR Paludisme). Author-
isation was granted by ANSM after artesunate attained
prequalification status from the WHO. Furthermore, a
protocol for therapeutic use and data collection (PTU)was set up for IV artesunate by ANSM in collaboration
with the distributor. This PTU serves three purposes: i)
to provide physicians and pharmacists with information
regarding the product and the conditions for its use, ii) to
describe and organise pharmacovigilance, and iii) to or-
ganise patient follow-up and data collection and analysis.
Availability of Malacef in the Netherlands, Belgium
and France
The availability of IV artesunate (Malacef ) by country is
shown in Figure 1. In the Netherlands, IV artesunate was
initially almost exclusively stocked in UMCs, and this was
quickly followed by teaching hospitals and general hospi-
tals, covering a large area of the Netherlands. In Belgium,
treatment using IV artesunate has been largely limited to
specialised centres (42% UMCs, 33% teaching hospitals),
whereas in France, 60% of the hospitals ordering IV
artesunate were CHUs (17 out of 32 CHU in France).
The cumulative availability of IV artesunate vials for
each country is plotted in Figure 2, and the availability
per capita is plotted in Figure 3. In the Netherlands, the
hospital stocks of IV artesunate per capita increased at a
faster rate than in Belgium and France (Figure 3). At the
end of 2012, availability per capita was 0.25 vials in the
Netherlands, 0.1 vials in Belgium and 0.06 vials in France.
Pharmacovigilance
In both Belgium and the Netherlands, pharmacovigilance
in NPPs relies on the obligatory reporting of passively de-
tected adverse events by individual physicians. Each pre-
scription of a non-registered medicinal product must be
accompanied by a statement from the physician who ac-
cepts responsibility for monitoring and reporting the drug’s
efficacy and adverse events (if any occur). This passive no-
tification system is quite different from the pro-active sys-
tem in France, in which each newly treated patient must be
authorised and must be actively followed with respect to
pharmacovigilance.
Although this was not required, patients who were
treated with IV artesunate in the Netherlands and Belgium
from November 2007 through December 2010 were pro-
actively traced in order to assess outcome [7]. Of the 68
patients who were treated (including 55 patients with
severe malaria), two patients died (2/55 = 3.6%). The treat-
ment was generally well-tolerated, and most of the rec-
orded complications were compatible with the clinical
findings associated with severe malaria and were present
before IV artesunate treatment had started; therefore,
these complications were not recorded as being related to
the use of IV artesunate. It is noteworthy that seven pa-
tients developed an atypical form of haemolytic anaemia
[7]. In the period of 2010 through 2012, only passive sur-
veillance (i.e. spontaneous reporting) was performed, and
no adverse events were reported. The haemolytic anaemia
Table 1 Implementation of NPPs in the Netherlands, Belgium and France
Category Determinants The Netherlands Belgium France




Article 6 quarter §1, 1° of the law
on medicinal products of 25/03/
1964, revised on 01.05.2006 and
its Royal Decree dated 14/12/2006
(Art. 102 and 105).
Article L.5121-12 a of the French
Public Health Code
Jurisdiction Health Care Inspectorate (IGZ) FAMHP (Federal Agency for
Medicines and Health Products)
ANSM (French National Agency
for Medicines and Health Products
Safety; under the supervision of
the Ministry of Health).
Legal entities that can
apply for an NPP
-Manufacturers The licence-holder as defined in
Art 74 of the Royal Decree dated
14/12/2006.
Request of the prescribing
physician submitted to ANSM by a
pharmacist at the healthcare institution.-Wholesalers
-Pharmacists
-Dispensing general practitioners
The applicant must be domiciled
or have a registered office in the
Netherlands.
Application Application must be accompanied
by documents to enable
assessment of safety, therapeutic
rationale and (non-) substitutability
of the product. The first
application must be accompanied
by a declaration signed by the
prescribing medical doctor in
which the doctor agrees to be
fully responsible and to accept the
risks of prescribing an unlicensed
medicinal product.
Authorisation for importation,
distribution and delivery of
unauthorised medicinal products
is obtained through an unsolicited
request (medical statement) from
a healthcare professional for use
in a particular patient. The
initiation and conduct of the
treatment falls under the full
responsibility of the treating physician.
A ‘nominative’ ATU is issued for a
named patient, and upon the
request and responsibility of the
prescribing physician. The request
form is accompanied by a
prescription, the patient’s clinical
history and a justification for using
the drug, and is submitted by the
hospital pharmacist. ANSM must
authorise the ATU for each patient
and reserves the right to modify






The licence-holder as defined in
Art 74 of the Royal Decree dated
14/12/2006 at the request of a
pharmacist based on a prescription
for a properly defined patient.
Only hospital pharmacists may
supply the medicinal product
subject to an ATU.
Pharmacovigilance Entity demanding
pharmacovigilance
The Inspectorate The Belgian Centre for
Pharmacovigilance for medicines
for Human use (BCPH), which is
part of the FAMHP.
ANSM
Patient follow-up and data
collection
The Inspectorate asks suppliers to
report annually the number of
patients treated with the specified
unregistered product
Unspecified ANSM requires a medicinal
product dossier beforehand from
the pharmaceutical company in
order to establish a predefined
protocol for therapeutic use (PTU),
specifying the conditions for use,
patient follow-up and the collection




















Table 1 Implementation of NPPs in the Netherlands, Belgium and France (Continued)
Reporting adverse events Adverse reactions suspected to be
related to the medicinal product
must be reported to the
Inspectorate by the treating
physician (specified in the doctor’s
declaration)
Adverse reactions suspected to be
related to the medicinal product
must be reported to BCPH by the
treating physician (specified in the
doctor’s declaration).
Any physician, pharmacist, dentist or
midwife observing a serious or
unexpected adverse reaction that
could be due to the medicinal product
with an ATU should notify the regional
pharmacovigilance centre (CRPV) to
which the reporter is geographically
linked with or the addressee indicated




A manufacturer, wholesaler or
pharmacist who has been granted
permission to supply an
unregistered product is required
to record all reported side effects
(Art 3.17), which should be
reported to the Inspectorate
The Belgian Centre for
Pharmacovigilance for medicines for
Human use (BCPH) is responsible for
the coordination of various tasks
related to pharmacovigilance. No
further details (website page under
construction)
As defined in the PTU, although mostly
Regional Pharmacovigilance Centres
(CRPV) collect and assess the
information and transmit it to ANSM.
The ATU may be suspended or
withdrawn by the Director General of
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Figure 1 Distribution of IV artesunate availability in the Netherlands (NE), Belgium (BE) and France (FR) by type of hospital. CHU, centre
hospitalier universitaire; UMC, university medical centre.
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with malaria and its treatment; the data collection was not
designed specifically to capture this effect.
In France, the use of IV artesunate is subject to a protocol
describing its therapeutic use, and pharmacovigilance is co-
ordinated by the CNR Paludisme, Paris [14]. A total of 113
patients were treated for severe malaria with IV artesunate
in the period from May 2011 through November 2012 [15].
The clinical course of the disease was favourable in 107 pa-
tients. The other six patients died in a very late stage of the
disease while receiving IV artesunate therapy; two of these
six patients were initially treated with IV quinine.
Twenty-seven patients experienced an episode of an-
aemia, including 15 cases of delayed and/or persistent
haemolytic anaemia. One patient suffered from severe
disseminated intravascular coagulation (DIC) with necrosis
and amputation of fingers and legs in combination with a
minimally conscious state. Furthermore, cytolytic hepatitis
(three patients), cardiac involvement (transient bradycardia
and QTc prolongation), rash (one patient), vision impair-
ment (one patient), transient hyperkalaemia (one patient)
and cerebellar ataxia (one patient) were also reported.
Discussion
This article describes the roll out of Malacef (IV arte-
sunate) under named patient programmes in three EU
member countries. France has a system that uses proactive
authorisation and surveillance, whereas Belgium and the
Netherlands depend on the passive detection of adverse
events. Most patients are treated at academic medical
centres, but more specialised general hospitals also have
IV artesunate in stock. The geographical distribution of
Malacef throughout the Netherlands was relatively rapid,
which is not surprising for a small country in which theprofessional groups are highly organised. In Belgium and
France, the geographical distribution of Malacef proceeded
more slowly. In Belgium, this is due to the fact that the use
of Malacef is restricted to select specialised centres; in
France, the slow distribution was likely due to a centralised
procedure that is tightly controlled by the French govern-
ment and requires strict and therefore lengthy application
procedures.
The major limitations of NPPs include their non-
centralised design and uncontrolled setting, particularly
in the Netherlands and Belgium. However, our study
shows that the investigator-initiated pharmacovigilance
studies that were added to the NPPs in the Netherlands
and Belgium [7] as well as in Germany [16] combined
clinical expertise with a certain degree of serendipity sen-
sitive enough to detect a new adverse event. Haemolysis is
not uncommon in the reconvalescent phase of malaria
[17]. Because the treating physicians see only individual
cases, this form of haemolysis became apparent only after
data pooling and trend analysis. In this particular case, the
routine individual adverse event reporting in the Dutch
and Belgian NPP legislations would have been too passive
to identify this unusual adverse event.
On the other hand, formatted data collection studies
such as clinical trials may only detect what they are de-
signed to detect [18]. It is noteworthy that this adverse
event was not described in the two largest trials that were
conducted regarding both adults and children with severe
malaria in endemic regions [2,3], although these trials
were not designed to detect this late-onset event. It should
be emphasised that the present study only reflects the
situation in three EU member countries and that a named
patient programme is not necessarily a suitable substitute
for prospective clinical trials.
Figure 2 Cumulative number of vials of IV artesunate distributed to A) the Netherlands, B) Belgium and C) France based on
distribution records from ACE Pharmaceuticals.
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demic institutions and pharmaceutical companies are often
criticised due to concerns regarding financial ties to indus-
try that may influence professional judgement with respect
to patient care, medical research and/or education. How-
ever, academia-industry collaborations have also led to im-
portant and beneficial advantages in healthcare and are
essential to the continued development of orphan drugs.
Indeed, without this collaboration, IV artesunate might still
not be available in Europe. Dutch clinicians were highly
motivated to introduce IV artesunate in Europe becausethey witnessed first-hand the efficacy of IV artesunate in
treating severe malaria. These clinicians formed a collabor-
ation with a pharmaceutical company that specialises in
the import of medical need products, and their efforts led
to the legal import of IV artesunate from Guilin (in China)
into the Netherlands and its export, after release, to other
EU member countries.
NPPs have various positions within the European phar-
maceutical legal and organisational frameworks [19]. The
differences in the NPPs in the various EU member coun-
tries have led to differences in the availability of IV
Figure 3 Availability of IV artesunate per capita in the Netherlands (NL), Belgium (BE) and France (FR). Availability was calculated using the
following formula: [([the number of IV artesunate vials ordered per country)/ (the total population of that country)x1000]. Q1, first quarter of year.
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has enjoyed a privileged position compared to the rest of
Europe. Dutch patients have had access to Malacef since
2007, and Belgium followed in 2009; France received per-
mission to use IV artesunate in April 2011. In the second
half of 2012, Switzerland set up an NPP that was permitted
by SwissMedic. Other countries are still debating this topic.
This difference among EU member countries is based on
the differences in national legislation and the approaches
used to implement NPPs, as well as on various countries’
hesitation to use the product. For example, whether data
collected from endemic regions can be extrapolated to the
European population has been a subject of debate, and a
comparative trial of parenteral artesunate versus quinine in
the European patient is believed to be both unethical and
unfeasible due to the relatively low incidence of malaria in
Europe [4]. Nevertheless, the European Medicines Agency
(EMA) and other national drug regulators depend on com-
parative trials as the primary instrument with which to col-
lect the evidence needed for market authorisation, and
NPPs are not embraced to the same extent as research
studies. The French legislation even explicitly mentions
that the use of medicinal products that are subject to an
ATU cannot replace a clinical trial and that the goal of an
ATU is not one of investigation. However, as revealed in
this study, the pharmacovigilance component of NPPs can
provide enormously valuable data, and their usefulness
from a regulatory point of view should not be dismissed.
For example, the safety data regarding one out of every
seven European-approved orphan drugs were derive from
such programmes [20]. NPPs represent a bridge between
the controlled trial environment and real-world use and
can even increase sensitivity for detecting adverse events.
Because the enrolment of patients in NPPs is usually
initiated by physicians, the pharmaceutical companiesusually have little influence on the process [6]. However,
the manufacturer can play an important role in the
collecting and sharing of data regarding the drug’s safety
and efficacy. Although Guilin’s artesunate received WHO
prequalification in 2010, it is worth noting that sterility is-
sues of one batch of the product led to a worldwide “rapid
alert” action on the initiative of the Dutch Pharmaceutical
Inspection in May 2012 which amongst others resulted in
a recall in several countries. Therefore, before being re-
leased for distribution, each batch of imported IV
artesunate is subjected to a series of both physicochemical
quality controls and sterility tests in accordance with Euro-
pean Pharmacopeia requirements. Furthermore, drug dis-
tribution must be controlled, and supplies must be
transparent to ensure that there is no trading. Finally,
pharmacovigilance data must be collected, and risks should
be anticipated as much as possible [6].
In France, although it is both time-consuming and
tedious, a proactive authorisation system is in place, and
pharmacovigilance is designed to be much stricter
with respect to data collection. In Belgium and the
Netherlands, on the other hand, the NPPs were
implemented relatively quickly, and surveillance has re-
lied on reporting by physicians. Without guidance or
legal enforcement to actively require physicians to report
adverse event, this system is prone to underreporting
[21]. In addition, without aggregating individual observa-
tions and/or the sharing of knowledge, identifying a po-
tential link between an apparent adverse reaction and a
drug is more difficult. Indeed, if an active follow-up had
not been initiated in Belgium and the Netherlands, the
haemolytic anaemia that was recently described in seven
patients would not have been detected. Although these
reported cases of late-onset haemolysis recovered with-
out sequelae, and although anaemia is likely attributable
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[22], additional safety data are needed.
The present study illustrates that similar to full-market
authorization, NPPs require a reliable pharmacovigilance
system that captures all data, follows all patients and al-
lows scientists to study and identify adverse event pat-
terns. Because of the rarity of the disease and patients, it is
imperative that all patients who are treated in an NPP can
be easily identified and monitored at all times, and pa-
tients should therefore be registered in order to minimize
any loss of data. This can be achieved by requiring an elec-
tronic database to keep track of electronic prescriptions
for each patient who receives treatment with an unau-
thorized medicine. The prescribing physician can also
register his/her medical license number and can file the
prescription with a code that will allow the physician to
identify and track the patient. Using this approach, both
the patient and the physician are traceable at all times. In
addition, the unauthorised medicine would only be dis-
pensed by a pharmacist when such an electronic prescrip-
tion is available, and this should be strictly controlled (and
the pharmacist should be sanctioned if the proper proce-
dures are not followed). The manufacturer and/or distribu-
tor can play a pivotal role in facilitating the connection
between the product’s distribution and its registration in
the database.
New legislation should be introduced throughout the
EU in order to both optimize and harmonize the phar-
macovigilance of orphan and other unregistered products.
Harmonization should ensure equal availability of the
treatment and therapeutic benefit to all Europeans. Efforts
must be made to both simplify and accelerate access to
NPP drugs particularly in emergency situations such as
severe malaria in order to save valuable time for patients
in need. This ambitious yet attainable goal can only be
achieved through close cooperation among prescribers,
pharmacists, academia, industry and in particular the drug
regulators, who should take the lead. In this respect, we
feel that the EMA has two important roles to play: first, in
facilitating and implementing these new EU rules, and
second, in exploring how NPPs can contribute to the
registration of orphan drugs.
Conclusions
IV artesunate has rapidly gained its place in the treat-
ment of severe malaria in the Netherlands, and other
countries are following (albeit hesitantly). This hesitation
is due to both differences in the implementation of NPP
legislation and the knowledge gap with respect to using
IV artesunate to treat European patients.
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